Skip to main content

Table 1 Baseline characteristics of the AS study population

From: Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

  Total IFX ETA ADA
Number of patients 220 32 137 51
Age (yrs) 42.9 ± 11.9 45.8 ± 10.1 41.9 ± 11.6 43.7 ± 13.3
Gender (male) (n, %) 152 (69) 20 (63) 96 (70) 36 (71)
Duration of symptoms (yrs) 15 (1 to 53) 21 (2 to 49) 15 (1 to 47) 11 (1 to 53)
Time since diagnosis (yrs) 7 (0 to 45) 16 (0 to 35)* 7 (0 to 44) 6 (0 to 45)
HLA-B27+ (n, %) 174 (81) 24 (75) 108 (82) 42 (82)
History of IBD (n, %) 20 (9) 8 (26)† 7 (5) 4 (8)
History of uveitis (n, %) 64 (29) 13 (40) 44 (32) 7 (14)‡
History of psoriasis (n, %) 13 (6) 3 (9) 8 (6) 13 (6)
Peripheral arthritis (n, %) 37 (17) 5 (16) 27 (20) 5 (10)
Current NSAID use (n, %) 158 (72) 24 (75) 102 (75) 32 (63)
Current DMARD use (n, %) 45 (21) 10 (31) 28 (20) 7 (14)
BASDAI (range 0 to 10) 6.1 ± 1.7 6.1 ± 1.4 6.2 ± 1.7 5.9 ± 1.7
ASDAS 3.8 ± 0.8 3.8 ± 0.6 3.8 ± 0.8 3.7 ± 0.9
Physician's GDA (range 0-10) 5 (0 to 9) 5 (0 to 8) 5 (0 to 9) 3 (0 to 9)‡
Patient's GDA (range 0 to 10) 7 (1 to 10) 6 (1 to 9) 7 (1 to 10) 6 (1 to 10)
ESR (mm/h) 21 (2 to 101) 24 (2 to 90) 20 (2 to 101) 23 (2 to 74)
CRP (mg/l) 13 (2 to 99) 15 (2 to 74) 12 (2 to 99) 14 (2 to 92)
BASFI (range 0 to 10) 6.1 (0.3 to 9.7) 6.3 (1.9 to 9.6) 5.9 (0.3 to 9.7) 6.3 (0.4 to 9.5)
Chest expansion (cm) 3.0 (0.5 to 43.0) 2.5 (0.5 to 7.0) 3.0 (0.5 to 22.0) 3.5 (0.0 to 43.0)§
Modified Schober test (cm) 2.9 (0.0 to 7.0) 2.4 (0.5 to 6.0) 2.8 (0.1 to 7.0) 3.2 (0.0 to 5.5)
Occiput to wall distance (cm) 4.9 (0.0 to 34.5) 9.0 (0.0 to 26.0)^ 4.5 (0.0 to 34.5) 3.5 (0.0 to 30.0)
Lateral lumbar flexion L (cm) 8.0 (0.0 to 30.0) 7.0 (2.0 to 15.0) 9.0 (0.0 to 30.0) 8.0 (1.0 to 20.5)
Lateral lumbar flexion R (cm) 8.0 (0.0 to 29.0) 8.0 (0.5 to 17.0) 8.0 (0.0 to 29.0) 7.5 (1.0 to 20.0)
  1. Values are mean ± SD or median (range) unless otherwise indicated.
  2. AS, Ankylosing Spondylitis; IFX, infliximab; ETA, etanercept; ADA, adalimumab; HLA-B27+, human leukocyte antigen B27 positive; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; DMARD, disease-modifying antirheumatic drug; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; GDA, global disease activity; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASFI, Bath Ankylosing Spondylitis Functional Index; L, left; R, right.
  3. * P < 0.05 compared to ETA group and P = 0.052 compared to ADA group.
  4. P < 0.05 compared to ETA group and P = 0.050 compared to ADA group.
  5. P < 0.05 compared to IFX and ETA groups.
  6. § P < 0.05 compared to ETA group.
  7. ^ P < 0.05 compared to ETA and ADA groups.